Roche, Indianapolis, introduces a new test to assess a patient’s viral load of cytomegalovirus (CMV).

Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically, patients with an immune system that has been suppressed for solid organ transplantation.

The test received premarket approval from the FDA in July.

The real-time polymerase chain reaction (PCR)-based CMV test provides standardization of CMV viral load monitoring with traceability to the WHO International CMV standard. It is designed for use on Roche’s fully automated COBAS AmpliPrep/COBAS TaqMan System, an established platform for viral load monitoring of multiple infectious diseases that helps laboratories improve their workflow.

The system can be combined with the cobas p 630 Instrument, which provides an integrated preanalytical primary tube handling solution.

[Source: Roche]